YOLFTbeta
68

Shanghai Rendu Biotechnology Co. Ltd. A

688193 · SHG · Healthcare / Diagnostics & Research

42.94CNY-1.36 (-3.07%)

Price History

Full chart

Market Stats

Previous Close44.30
Open44.35
Day Range42.87 – 44.78
52-Week Range40.00 – 62.36
Volume445.17K
Market Cap2.09B
P/E (TTM)111.04
Forward P/E0.00
EPS0.47
Dividend Yield2.40%
Beta0.36
50-Day Avg47.04
200-Day Avg50.97

About

Shanghai Rendu Biotechnology Co., Ltd. engages in the research, development, production, and sales of molecular diagnostic reagents products and supporting equipment in China and internationally. Its products are used in various therapeutic areas, including reproductive tract, respiratory tract, enterovirus infections, and bloodborne infectious diseases, as well as tumor auxiliary diagnosis. The company was founded in 2007 and is based in Shanghai, China.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEOMr. Jinliang Ju
  • Employees235
  • HeadquartersBuilding 15, Shanghai, China, 201201, China
  • Websitehttps://www.rdbio.com

Leadership

  • Mr. Jinliang JuChairman of the Board & Chief Scientist · b. 1966
  • Ms. Minghui YuGM & Director · b. 1983
  • Mr. Tingjiang CaiAccounting Officer, Accounting Supervisor, CFO & Secretary · b. 1974
  • Ms. Ruohua CaoDeputy GM & Director · b. 1966
  • Ms. Zhenling CuiSenior Director of R&D · b. 1978
  • Mr. Hao JinDeputy Director of Instrument R&D Department · b. 1990
  • Ms. Chang E ZhangRegistration Director & Director of Manufacturing Center · b. 1980

Financials

Income Statement

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue99.17M249.90M292.31M303.85M164.41M177.35M161.94M
Growth (%)-+152.00%+16.97%+3.95%-45.89%+7.87%-8.69%
Cost of Revenue11.04M60.30M74.18M104.74M30.82M36.38M35.56M
Gross Profit88.13M189.61M218.13M199.11M133.59M140.97M126.38M
Gross Margin88.87%75.87%74.62%65.53%81.26%79.49%78.04%
Operating Expense84.73M120.88M148.09M180.16M141.92M153.07M140.65M
Operating Income3.40M68.73M70.04M18.95M-8.32M-12.09M-14.27M
Operating Margin3.43%27.50%23.96%6.24%-5.06%-6.82%-8.81%
EBITDA7.63M76.12M82.92M41.71M20.98M2.19M26.84M
EBITDA Margin7.69%30.46%28.37%13.73%12.76%1.23%16.57%
Net Income3.74M61.38M64.62M23.33M8.26M-7.81M10.09M
Net Income Margin3.77%24.56%22.11%7.68%5.02%-4.40%6.23%
R&D13.80M23.70M26.32M34.19M41.14M39.17M34.59M
R&D as % of Total Revenue13.91%9.48%9.00%11.25%25.02%22.08%21.36%
Interest Expense-87.28K261.71K355.47K431.20K290.93K236.40K
Interest Expense % of Total Revenue-0.03%0.09%0.12%0.26%0.16%0.15%

Balance Sheet

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets187.07M310.79M378.61M1.09B1.05B994.36M990.17M
Total Liabilities36.41M95.75M90.86M127.34M91.97M82.48M76.26M
Total Equity150.66M215.03M287.75M961.38M962.74M911.88M913.91M
Cash42.23M171.98M197.94M298.93M609.57M261.58M97.44M

Cash Flow

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow13.67M92.61M54.44M-4.09M17.19M24.39M22.41M
Capital Expenditure54.83M15.55M26.48M21.22M20.39M10.52M7.07M
Free Cash Flow-41.16M77.06M27.97M-25.31M-3.20M13.86M15.33M
Dividends Paid-138.10K53.16K-5.00M11.71M9.69M
FCF to OCF-301.22%83.21%51.37%618.57%-18.60%56.84%68.43%
Dividend Paid to FCF-0.18%0.19%--156.36%84.47%63.18%

Earnings

Report DateMar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023
EPS Estimate------
EPS Actual0.420.130.05-0.01-0.16-0.10
Surprise------
Timing------

Key Statistics & Ratios

Market Cap2.09B
Enterprise Value1.20B
Trailing P/E111.04
Forward P/E0.00
Price / Sales13.06
Price / Book2.22
EPS0.47
Book Value22.80
Revenue (TTM)160.14M
Gross Profit (TTM)123.76M
EBITDA14.98M
Profit Margin11.01%
Operating Margin-5.03%
Return on Equity1.96%
Return on Assets0.13%
Shares Outstanding40.07M
Shares Float18.18M
Beta0.36
Dividend Yield2.40%
Dividend Rate1.25
Payout Ratio244.68%

Dividends

20261×
1.00Jun 10, 2026
20252×
0.15Nov 26, 20250.10Jun 27, 2025
20242×
0.10Oct 30, 20240.20Jun 27, 2024
20231×
0.13Jun 16, 2023